Zepbound and Mounjaro are the same drug — tirzepatide, manufactured by Eli Lilly — sold under two names for two different FDA indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management (and, as of 2024, moderate-to-severe obstructive sleep apnea in adults with obesity). The molecule, the manufacturer, the pen device, and the dose range (2.5 mg to 15 mg) are identical.
The differences are entirely regulatory and commercial.
What's Actually Different
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Dose range | 2.5–15 mg | 2.5–15 mg |
| FDA indication | Type 2 diabetes | Chronic weight management + OSA |
| Insurance coverage | Wider (diabetes formulary) | Narrower (anti-obesity exclusions) |
| List price | ~$1,023/month | ~$1,059/month |
| Savings programs | Lilly copay card for commercial insurance | Lilly copay card + self-pay options |
In June 2025, Lilly introduced LillyDirect, offering Zepbound at approximately $399/month for self-pay patients — a significant price reduction intended to compete with compounded tirzepatide. This self-pay option bypasses insurance entirely and ships directly from Lilly's network.
The Regulatory Redundancy
The reason two identical products exist under different names is the FDA's indication-specific approval system. A drug approved for diabetes cannot be marketed for weight loss without a separate approval — even if it's the exact same molecule. Lilly conducted separate clinical trial programs (SURPASS for diabetes, SURMOUNT for obesity) to support each approval. The result: two boxes, two NDAs, two price points, one drug.
This system has real consequences for patients. A doctor who prescribes Mounjaro for weight loss is prescribing off-label — which is legal but may not be covered by insurance. A doctor prescribing Zepbound for weight loss is prescribing on-label — but the patient's plan may exclude anti-obesity medications. Same drug, same dose, different bureaucratic outcome.
If your insurance covers Mounjaro for diabetes management and you also want weight loss benefits, use Mounjaro — it's the same drug at the same doses. If you don't have diabetes, Zepbound is the on-label option for weight management, and Lilly's self-pay pricing makes it increasingly competitive with compounded alternatives. For patients without insurance coverage for either, compounded tirzepatide through telehealth remains the most affordable access point.
Sema $99/mo, tirz $133/mo at any dose. LegitScript certified, 503A+503B pharmacies. Free consult, free shipping, no membership. Also NAD+ and sermorelin. Code x7X72r saves $25.
$99/month at every dose — verified flat. LegitScript, FSA/HSA. No price jumps at maintenance.
Compounded sema $125/mo, tirz $199/mo. Brand-name Mounjaro/Zepbound available. Code Bilt35 = 35% off first order.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Individual results vary.